Clinical trial · Interventional
Individualized Pharmaceutical-care for Inpatients With Cancer Pain
Impact of Individualized Pharmaceutical-care on Medication Adherence and Outcome of Cancer Pain in Opioid-tolerant Inpatients
NCT03455023CI-TRIAL-00036541unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant inpatients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pharmaceutical care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- pharmaceutical care intervention group
- description
- Patients will receive individualized pharmaceutical care in addition to usual medical care.
- interventionNames
- Other: pharmaceutical care
- type
- NO_INTERVENTION
- label
- control group
- description
- Patients will receive usual medical care.
Primary outcomes (1)
- measure
- Change in medication adherence
- timeFrame
- Change from baseline at 1 month after discharge
- description
- The investigators will measure the change in medication adherence via Morisky Scale. Morisky Scale contains 4 questions, and the total score ranges from 0 to 4 with lower scores indicating higher adherence.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 years or older; * Histologically confirmed solid tumor; * Diagnosed chronic cancer pain; * Opioid-tolerant patients; * Overall survival is expected to be over 3 months; * Karnofsky performance score≥50; * Willing and able to comply with the protocol Exclusion Criteria: * Current pregnancy or breastfeeding; * Patients diagnosed with non-cancer pain; * Patients treated with patient-controlled analgesia; * Patients with pathological fracture, gastrointestinal obstruction, severe infection, non-opioid related intractable constipation; * Patients with mental disorder; * Creatinine clearance rate \<15mL/min; * ALT or AST ≥ 10 fold of upper limit of normal value
References
Publications (1)
- DERIVEDZheng X, Ding H, Xu S, Xie R, Liu Y, Zhai Q, Fang L, Tong Y, Sun J, Xin W, Wu N, Chen J, Shi W, Yang L, Li H, Shao J, Wang Y, Yu H, Zhang B, Du Q, Yang Y, Zhang X, Duan C, Zhao Q, Shi J, Huang J, Fan Q, Cheng H, Chen L, Kong S, Zhang H, Gong L, Zhang Y, Song Z, Yang Y, Zhou S, Huang C, Lin J, Wang C, Huang X, Wei Q, Sun Y, Huang P. Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled Trial. Pain Ther. 2022 Mar;11(1):241-252. doi: 10.1007/s40122-021-00342-0. Epub 2022 Jan 29. PMID 35092599